Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2026)

Sarepta Therapeutics' Tax Provisions history runs 10 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• In Q1 2026, Tax Provisions fell 80.91% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at -$40.2 million (down 147.64% YoY), while the FY2025 annual figure was $11.5 million, down 55.21% from the prior year.
• Tax Provisions was $12.2 million for Q1 2026 at Sarepta Therapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $64.0 million in Q1 2025 to a low of -$43.3 million in Q2 2025.
• Historically, Tax Provisions has averaged $4.0 million across 5 years, with a median of $4.9 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions jumped 8528.26% in 2022, then plunged 3625.0% in 2025.
• A 5-year view of Tax Provisions shows it stood at $7.9 million in 2022, then tumbled by 314.41% to -$17.0 million in 2023, then surged by 176.05% to $12.9 million in 2024, then plunged by 62.03% to $4.9 million in 2025, then surged by 148.58% to $12.2 million in 2026.
• The last three Tax Provisions figures came in at $12.2 million (Q1 2026), $4.9 million (Q4 2025), and -$14.1 million (Q3 2025), per Business Quant data.